Compare LOCO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | ZURA |
|---|---|---|
| Founded | 1980 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.3M | 455.4M |
| IPO Year | 2014 | N/A |
| Metric | LOCO | ZURA |
|---|---|---|
| Price | $13.44 | $4.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $14.17 | $13.00 |
| AVG Volume (30 Days) | 267.5K | ★ 617.8K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $401,701,000.00 | N/A |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $49.85 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $8.87 | $0.99 |
| 52 Week High | $15.90 | $7.25 |
| Indicator | LOCO | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 36.34 |
| Support Level | $13.42 | $4.36 |
| Resistance Level | $14.38 | $5.82 |
| Average True Range (ATR) | 0.53 | 0.35 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 24.50 | 27.39 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.